Diabetes mellitus has been linked with specific morphological and metabolic abnormalities in skeletal muscle in a fiber specific manner. Erythropoietin (EPO) is a glycoprotein hormone that regulates the development of erythrocytes through binding to a high affinity receptor expressed in erythroid progenitor cells. EPO receptor expression in non hematopoietic tissue, including skeletal muscle progenitor cells, raises the possibility of a role for EPO beyond erythropoiesis. So the aim of the present study was to evaluate the effect of EPO on skeletal muscle changes as a complication of type 1 diabetes mellitus in STZ-rat experimental model. Methods: 40 male Sprague Dawely rats were divided into 5 groups : control group , diabetic group (STZ-induced , 50 mg/kg I.P.), insulin treated diabetic ; (received 0.75 IU/ 100g body weight daily, S.C; for 4 weeks) , EPO treated diabetic; (received EPIAO® S.C , 200 I.U/Kg, 3 times weekly, day after day for 4 weeks),and insulin and EPO treated diabetic groups. At the end of the experiments, fasting blood glucose, insulin levels, lipid profile, contractile changes in soleus muscle and glucose transporter 4 (GLUT4) expression in soleus muscle were evaluated. Results: All biochemical parameters were improved in the group treated with insulin or EPO with greater improvement in insulin treated group. The greatest improvement was in the group treated with combined insulin and EPO. Contractile function of soleus muscle in diabetic group showed significant decrease in muscle tension either before or after fatigue, significant decrease in time taken to reach complete fatigue, significant increase in time taken to reach peak and in time taken to relax to 50% when compared with normal group. All parameters were improved in insulin treated and EPO treated groups, with greater improvement in insulin treated group. The greatest improvement was in combined insulin and EPO treated group. The reduced GLUT 4 expression in diabetic soleus muscle was significantly increased in insulin treated group as compared to EPO treated group, however combined EPO and insulin treated group showed greater increase in GLUT4 expression. Conclusion: The present results showed that, EPO injection improved hyperglycemia, hypoinsulinemia, hyperlipidemia, and skeletal muscle changes observed in STZinduced diabetes in rats. Therefore, EPO could be beneficial in managing diabetic disorders and the application of EPO in treatment of diabetes can be considered. 
Introduction
Diabetes mellitus has been linked with specific morphological and metabolic abnormalities in skeletal muscle in a fiber specific manner. The reduction in absolute force production in T1DM may be explained by a fiber type-specific atrophy, as slow-twitch or type I fibers exhibit minimal loss or a slight gain in fiber area, while fast-twitch fibers, especially the fatigable glycolytic (type IIB) fibers, exhibit the most severe atrophy (1) .
Hyperglycemia has a negative effect on skeletal muscle as it leads to proteins glycation and further Based on this background , the present study was designed to explore whether EPO therapy can reduce metabolic and contractile changes in soleus muscle in STZ-induced Type 1 DM rat model.
Material and Methods

Experimental animals:
Fourty Sprague Dawely male rats, weighting 150- Hyperglycemia and hypoinsulinemia were used to identify the success of the model. Animals with FBG >300 mg /dl were included in the study (20).
After STZ injection, rats were allowed to drink 10% glucose solution to prevent hypoglycemia (21). FBG was measured weekly during the whole experimental period with an Accu-check Go strip test using glucometer.
Collection of blood and tissue samples
At the end of experimental protocol, Rats were anethesitised with thiopental (I.P, 120 mg/kg).
Blood was collected from the heart. , left to coagulate and centrifuged at 3000 rpm for 30 minutes .Separated serum was stored at -20º C for biochemical analysis. 
Contractile changes in the soleus muscle:
BIOPAC was used determining the optimal force range for the experiment (force transducer 100 for soleus muscle).
Statistical analysis:
Data were analysed by SPSS software ver. 17
(IBM, US). The findings were expressed as the mean ± SD. Statistical analyses were undertaken using independent One-way ANOVA with posthoc tukey test. The t-test was used for two sample assuming unequal variances, which confirmed the statistically significant difference (p < 0.05). A Pvalue <0.05 was accepted statistically significant.
Results
As shown in table (1) 
Contractile functions:
Data was obtained by analysis of the recorded curves .In table (3), diabetic animals showed significant decrease in muscle tension either before or after fatigue (P=0.0001), significant decrease in time taken to reach complete fatigue (P=0.0001) that means rapid fatigue. However time taken to reach peak and time taken to relax 50% were significantly increased (P=0.0001) as compaired to control.
Diabetic rats treated with insulin , showed significant increase in muscle tension before fatigue (P=0.0001) and insignificant increase in tension after fatigue (P=0.933). Significant increase in time taken to reach complete fatigue was also observed (P=0.0001) , Also significant decrease in time to reach peak and time to reach 50% relaxation was observed (P=0.0001) as compared to diabetic non treated group.
EPO treatment also produced significant increase in muscle tension before fatigue (P=0. .027) and insignificant increase in tension after fatigue (P=0.
.927). Significant increase in time taken to reach complete fatigue was also observed (P=0.007).
significant decrease in time to reach peak and time to reach 50% relaxation was observed(P=0.0001) as compared to diabetic non treated group. 
PCR ( area ratio) (GLUT4 expression ratio):
Data was obtained by analysis of PCR bands by Another explanation may be due to antioxidantlike action of EPO (26) 
